License Agreements - Artizan Biosciences Inc (Details) - USD ($)	1 Months Ended			3 Months Ended			9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jan. 31, 2021	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2020
License and other agreements
Development milestone payment to be paid				$ 123,800,000			$ 123,800,000
Commercial milestone payment to be paid				1,270,450,000			1,270,450,000
Research and development				95,517,000		$ 52,845,000	238,468,000	$ 300,028,000
Artizan Biosciences Inc
License and other agreements
Maximum number of preferred shares (in shares)	45,950,601
Proceeds from sale of stock	$ 8,000,000
Artizan Biosciences Inc
License and other agreements
Research and development				$ 0		$ 0	$ 0	$ 0
Artizan Biosciences Inc | Series A2 Preferred Stock
License and other agreements
Preferred shares paid (in shares)			61,494
Preferred shares paid			$ 6,000,000
Preferred shares received (in shares)			34,472,031
Artizan Biosciences Inc | Collaborative arrangement
License and other agreements
Option price	$ 4,000,000
Development milestone payment to be paid		$ 20,000,000
Additional development milestone payment to be paid		10,000,000			$ 10,000,000
Commercial milestone payment to be paid		$ 150,000,000
Percentage of funds raised for program	80.00%
Additional capital raise required	$ 35,000,000
Artizan Biosciences Inc | Collaborative arrangement | Series A2 Preferred Stock
License and other agreements
Preferred shares received (in shares)	22,975,301
Artizan Biosciences Inc | Collaborative arrangement | Minimum
License and other agreements
Option price									$ 4,000,000
Artizan Biosciences Inc | Collaborative arrangement | Maximum
License and other agreements
Option price									$ 8,000,000